Takeda To Ditch Orexigen In Another Deal Exit?
This article was originally published in PharmAsia News
Executive Summary
It's starting to look like there may be an acrimonious divorce in store for Orexigen and its marketing partner Takeda, now that the Japanese pharma has said it won't pay for another costly cardiovascular outcomes study for their obesity drug Contrave after the first was halted.